0001764013-23-000125.txt : 20231027 0001764013-23-000125.hdr.sgml : 20231027 20231027160403 ACCESSION NUMBER: 0001764013-23-000125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231025 FILED AS OF DATE: 20231027 DATE AS OF CHANGE: 20231027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levine Mark S. CENTRAL INDEX KEY: 0001617236 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 231355500 MAIL ADDRESS: STREET 1: 1601 TRAPELO ROAD STREET 2: SUITE 284 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 4 1 wk-form4_1698437034.xml FORM 4 X0508 4 2023-10-25 0 0001764013 Immunovant, Inc. IMVT 0001617236 Levine Mark S. C/O IMMUNOVANT, INC. 320 W 37TH STREET, 6TH FLOOR NEW YORK NY 10018 0 1 0 0 Chief Legal Officer 0 Common Stock 2023-10-25 4 S 0 4107 34.66 D 310381 D On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.66 - $34.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. /s/ Eva Renee Barnett, attorney-in-fact for Mark S. Levine 2023-10-27